| Combination of | |
|---|---|
| Netupitant | NK1 receptor antagonist |
| Palonosetron | 5-HT3 receptor antagonist |
| Clinical data | |
| Trade names | Akynzeo |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a614053 |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Netupitant/palonosetron, sold under the brand name Akynzeo, is a fixed-dose combination medication used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [7] [9] It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist. [10]
The capsules contain netupitant and palonosetron hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride. [11] [7] [8]
Contraindications
Netupitant/palonosetron may be contraindicated during pregnancy. [12] [1] [13]
Adverse effects
The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness. [7] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant. [12]
Interactions
Pharmacology
History
Netupitant/palonosetron was approved for use in the United States in October 2014. [14] It was approved for use in the European Union in May 2015. [8] The intravenous version, which contains the prodrug fosnetupitant in place of netupitant, was approved in the United States in April 2018. [15] [11]
References
- ^ a b "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020.
- ^ AusPAR: Netupitant / Palonosetron (as hydrochloride). Therapeutic Goods Administration (TGA) (Report). October 2020. Archived from the original on 9 September 2017. Retrieved 10 June 2022.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
-
^
"Archived copy" (PDF).
Archived (PDF) from the original on 10 June 2022. Retrieved 10 June 2022.
{{ cite web}}: CS1 maint: archived copy as title ( link) - ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ a b c d "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
- ^ a b c "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release). U.S. Food and Drug Administration (FDA). 10 October 2014. Archived from the original on 1 February 2017. Retrieved 16 December 2019.
- ^ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 26 June 2016. Retrieved 12 July 2016.
- ^ a b "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020.
- ^ a b Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
- ^ "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
| Combination of | |
|---|---|
| Netupitant | NK1 receptor antagonist |
| Palonosetron | 5-HT3 receptor antagonist |
| Clinical data | |
| Trade names | Akynzeo |
| AHFS/ Drugs.com | Monograph |
| MedlinePlus | a614053 |
| License data | |
|
Pregnancy category |
|
|
Routes of administration | By mouth, intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Netupitant/palonosetron, sold under the brand name Akynzeo, is a fixed-dose combination medication used for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. [7] [9] It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist. [10]
The capsules contain netupitant and palonosetron hydrochloride. The intravenous version is a combination of fosnetupitant chloride hydrochloride and palonosetron hydrochloride. [11] [7] [8]
Contraindications
Netupitant/palonosetron may be contraindicated during pregnancy. [12] [1] [13]
Adverse effects
The most common side effects include headache, weakness, fatigue, upset stomach, constipation, and skin redness. [7] The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant. [12]
Interactions
Pharmacology
History
Netupitant/palonosetron was approved for use in the United States in October 2014. [14] It was approved for use in the European Union in May 2015. [8] The intravenous version, which contains the prodrug fosnetupitant in place of netupitant, was approved in the United States in April 2018. [15] [11]
References
- ^ a b "Netupitant / palonosetron (Akynzeo) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 December 2019. Retrieved 19 March 2020.
- ^ AusPAR: Netupitant / Palonosetron (as hydrochloride). Therapeutic Goods Administration (TGA) (Report). October 2020. Archived from the original on 9 September 2017. Retrieved 10 June 2022.
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
-
^
"Archived copy" (PDF).
Archived (PDF) from the original on 10 June 2022. Retrieved 10 June 2022.
{{ cite web}}: CS1 maint: archived copy as title ( link) - ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Akynzeo 300 mg/0.5 mg hard capsules - Summary of Product Characteristics (SmPC)". (emc). 11 February 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ a b c d "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
- ^ a b c "Akynzeo EPAR". European Medicines Agency (EMA). 19 March 2020. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy" (Press release). U.S. Food and Drug Administration (FDA). 10 October 2014. Archived from the original on 1 February 2017. Retrieved 16 December 2019.
- ^ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Archived (PDF) from the original on 26 June 2016. Retrieved 12 July 2016.
- ^ a b "Drug Trials Snapshots: Akynzeo". U.S. Food and Drug Administration (FDA). 11 May 2018. Archived from the original on 24 January 2020. Retrieved 19 March 2020.
- ^ a b Haberfeld H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln.
- ^ "Fosnetupitant / palonosetron (Akynzeo for Injection) Use During Pregnancy". Drugs.com. 22 October 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "Drug Approval Package: Akynzeo (Netupitant and Palonosetron) Capsules NDA #205718". U.S. Food and Drug Administration (FDA). 7 November 2014. Archived from the original on 19 March 2020. Retrieved 19 March 2020.
- ^ "Drug Approval Package: Akynzeo (fosnetupitant and palonosetron) Injection". U.S. Food and Drug Administration (FDA). 31 May 2018. Archived from the original on 19 March 2020. Retrieved 19 March 2020.